Simris Group
0.09 SEK
-8.74 %
Less than 1K followers
SIMRIS B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Simris Group
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 1.7 | 2.2 | 6.1 | 4.1 | 4.4 | 2.9 | 1.6 |
| growth-% | 24.3 % | 183.3 % | -33.5 % | 6.6 % | -33.6 % | -44.1 % | |
| EBITDA | -20.3 | -20.7 | -23.1 | -18.0 | -22.4 | -17.6 | -15.5 |
| EBIT | -23.4 | -23.7 | -28.9 | -24.7 | -36.6 | -34.7 | -29.6 |
| Profit before taxes | -25.8 | -25.5 | -28.3 | -25.8 | -40.6 | -38.2 | -30.0 |
| Net income | -25.7 | -25.6 | -28.4 | -24.4 | -37.3 | -34.6 | -26.8 |
| EPS | -1.00 | -0.40 | -0.24 | -0.13 | -0.11 | -0.10 | -0.03 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -1,165.2 % | -954.0 % | -376.8 % | -441.4 % | -514.3 % | -608.7 % | -962.2 % |
| EBIT-% | -1,344.6 % | -1,093.9 % | -471.4 % | -604.4 % | -842.3 % | -1,201.0 % | -1,830.5 % |
| ROE | -71.1 % | -54.0 % | -155.6 % | -106.0 % | -145.7 % | -613.7 % | 5,704.5 % |
| ROI | -48.3 % | -44.9 % | -97.1 % | -13.1 % | -21.4 % | -22.0 % | -18.1 % |